InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,131.18
(
1.32%
)
US TECH 100
17,437.20
(
2.12%
)
Dow Jones
38,700.87
(
1.24%
)
Brent Oil
82.80
(
-0.99%
)
Bitcoin
61,866.48
(
4.64%
)
Post# of 251698
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119559
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 107367

Wednesday, 03/02/2011 2:13:45 AM

Wednesday, March 02, 2011 2:13:45 AM

Post# of 251698
Ipsen’s 4Q10 worldwide Dysport sales were €43.7M ($60M), -16% QoQ, -3% YoY.

The sharp decline from 3Q10 to 4Q10 was presumably due in part to channel destocking. More important, Dysport continues to be a very distant second to Botox, which had worldwide 4Q10 sales of $386M.

After adding in US sales of Dysport for cosmetic indications, which are booked by MRX, Botox is outselling Dysport worldwide by about 4:1.

Source: http://www.ipsen.com/sites/default/files/communiques-financier/PR-Full%20Year%202010%20Sales%20FINAL_0.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up